Objective: HIV-1 viral proteins and host inflammatory factors have a direct role in neuronal toxicity in vitro; however, the contribution of these factors in vivo in HIV-1-associated neurocognitive disorder (HAND) is not fully understood. We applied novel Systems Biology approaches to identify specific cellular and viral factors and their related pathways that are associated with different stages of HAND. Results: MND and HAD were associated with specific changes in mRNA transcripts and microRNAs in PBMCs. Comparison of upstream regulators and TimePath analyses identified specific cellular factors associated with MND and HAD, whereas HIV-1 viral proteins played a greater role in HAD. In addition, expression of specific microRNAs -miR-let-7a, miR-124, miR-15a and others -were found to correlate with mRNA gene expression and may have a potential protective role in asymptomatic HIV-1-seropositive individuals by regulating cellular signal transduction pathways downstream of chemokines and cytokines.
Introduction
HIV-1-associated neurocognitive disorder (HAND) is one of the major comorbidities of HIV-1 infection. HAND includes a spectrum of clinical manifestations associated with cognitive and behavioral impairments, based on increasing severity, classified as asymptomatic neurocognitive disorder (ANI), mild neurocognitive disorder (MND) and HIV-associated dementia (HAD) [1] . These clinical manifestations are the consequence of progressive loss of neurocognitive function [2] . Nearly half of the HIV-1-infected population is known to have some degree of HAND [3, 4] , and understanding how HIV-1 contributes to neuronal dysfunction remains a priority. HIV-1 infiltrates the central nervous system (CNS) early in the infection crossing the blood brain barrier via a 'Trojan horse' mechanism, involving infected monocytes/macrophages [5, 6] . This enables infection of other CNS-resident monocytic cells including microglia and perivascular macrophages [7] [8] [9] . Infiltration of monocytes into brain and associated inflammatory and metabolic toxicity is the hallmark of HAND that results in neuronal degeneration, apoptosis and associated changes [10] . HAART has drastically reduced dementia and brain disorder; however, the prevalence of ANI and MND remains high in HIV-1-positive individuals [3, 4] . The factors contributing to neuropathogenesis and/or HAND are not fully characterized. Although neurons are not primary target cells of HIV-1 infection, they express HIV-1 coreceptors (CCR5 and CXCR4). HIV-1 viral proteins (such as Tat, Vpr, and Env-gp120) and inflammatory factors (TNF-a, IL-8, IL-1b, IL-6 and others) contribute to neuronal toxicity from Ca 2þ reflux, nitric oxide production, and excitotoxicity [11] [12] [13] [14] [15] . In-vitro studies have identified the neurotoxic effects of viral proteins, inflammatory and metabolic agents; however, critical factors contributing to neuropathogenesis in vivo are not completely understood. Polymorphism in TNF-a gene that results in increased secretion in response to bacterial lipopolysaccharide has been observed with increased frequency in HIV-1-seropositive individuals with dementia [16] , whereas mutation in CCL2 (at position 2578G), CCR5D32 and other host factors have been identified as neuroprotective [1, [17] [18] [19] . Although recent work has studied the expression of microRNAs (miRNAs) in HAND response [20] [21] [22] [23] [24] , relatively little is known about their regulatory role and their targets.
Neuropathogenesis is determined by both neuroprotective and neurotoxic factors from infiltrating immune cells from the periphery, as well as resident microglial cells, astrocytes, neural support cells and cells of the bloodbrain barrier. Diverse viral quasispecies in infected individuals also play a role [25, 26] . Thus, outcome reflects numerous host and viral factors that interact with their cellular partners in multiple cell types. Most molecular interactions, especially those regulating basic cellular functions, are well conserved across multiple cell types; however, the functional effect is determined by epigenetic changes associated with different cell types. Therefore, it is plausible that neuroregulatory factors involved in HAND pathogenesis may be observed in immune cells of the peripheral blood compartment, as previously reported [27, 28] . Exposure of cells to neurotoxic or neuroprotective factors may result in transcriptome changes that include both short-term and long-term changes. Here, we performed global transcriptome analyses of peripheral blood mononuclear cells (PBMCs) obtained from HIV-1-seropositive individuals without clinical neurocognitive symptoms on standard neuropsychological testing, from those identified as MND or as HAD and from HIV-1-seronegative controls. Based on the results, we have defined the transcriptome changes in PBMCs associated with different stages of HAND and identified the potential contribution of host cellular factors and viral proteins in regulating HAND development.
Methods

Study population
Frozen PBMCs were obtained from participants of the Multicenter AIDS Cohort Study, as per the protocol [20, 29] þ cell counts (average and range) and viral load (average and range) at the time of sample collection are included in Table 1 . All the patients were men of unknown ethnicity.
mRNA profiling and data analysis Total RNA was isolated from PBMCs using the MirVANA kit (Applied Biosystems, Foster City, California, USA), as suggested by the manufacturer and was profiled with HT-12 V4 array bead chips (Illumina, San Diego, California, USA) as described previously [20, 30] . Datasets will be deposited in GEO database upon publication. Genome Studio was used to analyze the data and identify the differentially regulated gene transcripts. Rank invariant method and no background subtraction was included to normalize the data. In addition, the missing samples were excluded. A detection cutoff of p less than 0.01 was used. For calculating differential expression, the Illumina custom model was included along with multiple testing corrections using Benjamini and Hochberg False Discovery Rate. q less than 0.05 was considered as the cutoff to identify significantly regulated gene transcripts. IPA was used to determine gene interactions and correlation networks. Ingenuity knowledge base was included as the reference set and both direct and indirect interactions that were experimentally verified in humans or other animals including mouse, rat were considered for the analysis.
MicroRNA profiling and data analysis
The human microRNA microfluidic card set v3.0 (Applied Biosystems) was used for miRNA profiling of samples, as described previously [20] . Detectability threshold for miRNA assays was set to C T value less than or equal to 36 in at least 75% of all samples in each group. Differentially expressed miRNA between different groups were identified using parametric t test or LIMMA (Linear models for Microarray data; one factor analysis) with Benjamini-Hochberg false discovery rate method adjusted q values less than 0.05. MicroRNA target filter analysis from IPA was used to identify experimentally verified targets for the dysregulated miRNAs and correlated with the expression of dysregulated genes identified between the comparison groups. IPA-based canonical pathway and upstream analysis were used to identify the networks associated with miRNA targets and predict associated biological functions.
TimePath
TimePath reconstructs dynamic signaling and regulatory networks by integrating several diverse data sources, please see [31] for details of methodology, and Fig. S4 , http://links.lww.com/QAD/B34 for additional details. These include condition specific data (viral-host interactions and gene expression data) and general data (protein-protein and protein-DNA interactions) obtained from BIOGRID, HPRD and VirHostNet datasets [32] [33] [34] . To apply TimePath to this dataset, we constructed a gene expression series with the HIVseronegative, HIV-seropositive individuals who did not have HAND symptoms or MND or HAD in that order. Each phase consisted of one time point starting with the HIV-seropositive with no HAND time point for a total of three phases. Following prior work [31] , we extracted the top 200 DE genes for each phase relative to the previous phase. These DE genes were used as targets for the TimePath Integer Programming function. All the HIV-1 viral proteins were included as sources in the analyses. Results presented in Fig. 1e indicate that for HIV-1-positive individuals with MND or HAD -IFNg, TNFa, IL-2, CSF2, IL-27, IL-1b, CD40LG, IL-15, IFNA2, TGFb1 and others -cytokines are expressed at higher levels when compared with HIV-1-seronegative individuals. In addition, the activity of cytokines including TNFa, IL-2, CSF2, IL-1b, IL-15, IFNA2, TNFSF10/11 and IL-18 progressively increases with more severe forms of HAND (Z-score increases >40%). In contrast, the activity of IFNg, IL-27, CD40LG, KITLG and IL-6 remains unchanged with the two different stages of HAND (change in Z-score <40%). Interestingly, increased activity of LIF is observed only during MND and is not identified in HAD. TIMP1, which encodes for tissue inhibitor of metalloproteinases is predicted to be inhibited in HAD-positive individuals. Activity of prolactin was observed to be reduced (29% reduction The neurocognitive status of the patients was identified based on well established clinical neuropsychological testing conducted as part of MACS visit. CD4 þ cell count and viral load corresponds to the values at the time of sample collection. HAD, HIV-associated dementia; HAND, HIV-1-associated neurocognitive disorder; MACS, Multicenter AIDS Cohort Study; MND, neurocognitive disorder.
Fig. 1.
Comparison of differentially regulated genes (q < 0.05, false discovery rate adjusted) in HIV-1-seropositive individuals without HIV-1-associated neurocognitive disorder, with mild neurocognitive disorder or HIV-associated dementia relative to HIV-1-seronegative patients. (a) Schematic representation of relationship between different groups included in the study. HIV-1-seronegative individuals upon HIV-1 infection become HIV-1-seropositive and they can either be symptom-free (no HIV-1-associated neurocognitive disorder) or can develop asymptomatic neurocognitive disorder, mild neurocognitive disorder or HIV-associated dementia. The Venn diagram displays the number and overlap of significantly differentially expressed gene transcripts (q < 0.05, false discovery rate adjusted) among HIV-1-seropositive patients without HIV-1-associated neurocognitive disorder symptoms, with mild neurocognitive disorder or HIV-associated dementia compared with HIV-1-seronegative group. Total RNA isolated from peripheral blood mononuclear cells in these donors was characterized by Illumina HT-12 V4 array beadchips, and the data were analyzed using genome studio. Multiple probes for a single gene were combined together. A detection cutoff of P less than 0.01 was used to identify transcripts that were detected consistently in each group. The expression of RNA transcripts were compared between HIV-1-seropositive individuals with mild neurocognitive disorder and without HIV-1-in Z-score) in HAD relative to MND. Specific factors such as IL-5, IL-17A, CXCL2, AIMP1, IL-1a, CCL2, IL-12B, PF4 and IL-18 are predicted to be active only during HAD. Conversely, reduced activity of these cytokines and chemokines is associated with the HIV-1-seropositive individuals who never developed clinical HAND.
Similar analyses of kinases, phosphatases and associated signaling factors suggest that in individuals without HAND, EIF2AK3 and EIF2AK2 kinases exhibit reduced activity, whereas MAP4K4 has increased activity, similarly phosphatase SOCS3 and DUSP1 also had increased activity (Fig. 1f) . In individuals with MND, EIF2AK3 is activated but MAP4K4 and SOCS3 are reduced. In individuals with HAD, EIF2AK2 is active to a greater extent than in MND. Similarly, the activity of the transcription factors (TFs) -MYC, RELA, STAT1, XBP1, NFATC2 and IRF5 -increases with the severity of HAND, whereas the activity of CEBPA was reduced (more than 40% change in Z-score between MND and HAD). The activities of ZFP36 and SMAD7 are inhibited in HAD, whereas the activity of TFs -STAT3, IRF7, IRF3, IRF1, SREBF1, TRIM24, CNOT7 and NKX2-3 -did not change between MND and HAD individuals (Fig. 1g) . Together, these results identify multiple specific factors including cytokines, transmembrane proteins, receptors and associated transcription factors as the critical upstream regulators of genes that are associated with different stages of HAND.
mRNA and microRNA coexpression validates the upstream analysis and identifies neuroprotective microRNAs MicroRNAs along with other host cellular molecules including TFs and associated signaling molecules regulate host gene expression. Next, we evaluated the changes in miRNAs expression level and also analyzed the correlation between the expression of miRNAs and their predicted mRNA targets across the groups being compared. MiRNAs that were detected with C T value less than 36 cycles in at least 75% of the individuals within the group were included in the analysis. Comparison identified 74 miRNAs that were downregulated in HAD relative to HIV-1-seropositive group with no HAND, of which, 37 miRNAs decreased in HAD but increased in no HAND relative to HIV-1-seronegative. Five miRNAs decreased to a greater extent in HAND than in HANDnegative group. Although 32 miRNAs increased in both the HAND-negative and HAD groups with the increase in HAND-negative group greater than HAD group leading to an apparent downregulation of miRNAs in HAND (Fig. S3 , Tables S4 and S5, http://links.lww. com/QAD/B34).
Correlating miRNA and mRNA expression data between HIV-1-seropositive individuals with no neurocognitive disorder and with HAD identified 15 miRNAs that are both significantly dysregulated and regulate gene targets that are also significantly altered (Fig. 2a, Table S6 , http:// links.lww.com/QAD/B34). MiR-15a had 17 mRNAs targets and miR-124-3p targeted 14 mRNAs. MiRNAs including miR-210, miR-124-3p and let-7a-5p, which were predicted as upstream regulators in HAD by IPA (Fig. 2b) , were also validated as differentially dysregulated in our transcriptome analyses. Evaluating the association of the miRNAs and their gene targets with biological function identified their potential role in inhibiting chemokine signaling specifically IL-8, CXCR4 and Integrin (Fig. 2c) . Similarly, correlative analysis of mRNA : miRNA expression in HIV-1-seropositive individuals in comparison with HIV-1-seronegative individuals identified 21 miRNAs targeting 98 mRNAs in the no HAND group, whereas four miRNAs targeting 10 mRNA and five miRNAs targeting 30 mRNAs were found in MND and HAD groups. Further analysis of miRNA gene target with biological function determined that miRNAs upregulated in HAND-negative group are associated with multiple gene targets downstream of CSF2, IL-5, RELA, p38 MAPK, IL-3, IL-1B, TLR4, CXCR4 and IL-8 signaling (Fig. 2d , Table S7 , http://links.lww. com/QAD/B34), suggesting that the miRNAs upregulated in HIV-1-seropositive patients who do not develop HAND can potentially neutralize the downstream effect of many of these neuroinflammatory factors associated with HAND pathogenesis. In summary, these results suggest associated neurocognitive disorder (b) or with HIV-associated dementia and without HIV-1-associated neurocognitive disorder (c). Pie chart denotes the number of RNA transcripts consistently detected in both the comparing groups (blue), or detected only in comparing HIV-1-associated neurocognitive disorder positive group (red) or detected only in those without HIV-1-associated neurocognitive disorder (green) or not detected in both the comparing groups (yellow). The volcano plot represents the fold change in expression of RNA transcripts in HIV-1-associated neurocognitive disorder positive group over no HIV-1-associated neurocognitive disorder group for only those genes that are consistently detected in both the comparing groups. Dotted vertical line (red) corresponds to a two-fold cutoff, and the dotted horizontal line (green) corresponds to P ¼ 0.05. (d) The Venn diagram displays the number and overlap of significantly differentially expressed gene transcripts (q < 0.05, false discovery rate adjusted) among the mild neurocognitive disorder and HIV-associated dementia relative those without HIV-1-associated neurocognitive disorder. Red upward arrow indicates the increase, and the green downward arrow indicates the decrease in number of the gene transcripts. Comparison of gene transcript expression unique for these HIV-1-seropositive individuals with or without HIV-1-associated neurocognitive disorder identified multiple upstream regulators including -(e) cytokines and growth factors, (f) factors involved in signal transduction -kinases, phosphatase, ligand-associated nuclear receptors, membrane associated receptors, and (g) transcription factors. that certain miRNAs have a protective role in HAND, in which the upregulation of specific set of miRNAs is associated with reduced HAND pathogenesis.
HIV-1 viral proteins play a major role in modulating the transcriptome changes associated with HAD We next explored the contribution of HIV-1 viral proteins using TimePath analysis [31] . Results (Fig. S4 , http://links.lww.com/QAD/B34) identified CCND3, CDK4, CCND1, ESR1 and RB1 as the top five regulators of the transcriptome changes observed in MND (Table S8 , http://links.lww.com/QAD/B34). It can also be noted that HIV-1 Env is ranked higher than the other viral proteins at rank 26, with Gag-pol at 33 and Rev at 37. Similarly, analyses of the HAD stage, with the restriction to include the cellular networks associated with HIV-1-seropositive group and MND, show that the viral proteins are ranked relatively high (between ranks 20-39), suggesting that the viral proteins and/or virus infection may play a major role in progression of disease from MND and HAD. Other proteins that ranked high include the host protein CD4 þ , which is the main receptor of HIV-1 virus along with transcription factors including TP53, EP300, RELA, RB1 and ESR1, which are known to regulate virus replication, further strengthening the association of virus replication/infection with HAD (Fig. 3) . In addition, specific HIV-1 viral proteins were identified to regulate pathways: TRAF ! CD40 ! RNF31, CREBBP ! SREBF1 ! MYH9 and CEBPB/SUMO1 ! HSF1 ! HSPH1 (Table S9 , http:// links.lww.com/QAD/B34), which have been previously identified to regulate monocyte/macrophage chemotaxis, inflammation and regulation of intracellular signaling, these were identified during HAD. Interestingly, other significant pathways (Table S9 , http:// links.lww.com/QAD/B34) regulated by HIV-1 viral proteins, especially those regulating NRGN and CIRBP, were identified in patients who did not have HAND symptoms, whereas the rest of the other significant pathways were enriched in HAD (Table S9 , http:// links.lww.com/QAD/B34), suggesting that some of the early molecular events associated with neurological pathogenesis caused because of HIV-1 viral proteins are observed in PBMC in the absence of any HAND symptoms. The HIV-1 proteins regulating these pathways in HAD were due to Nef, Vpu and Env, whereas the changes in NRGN and CIRBP in HIV-seropositive patients with no HAND can be attributed to Tat, Vpr, Vpu, Vif, Nef and Gag-Pol.
Discussion
Identifying host and viral factors that influence neurological progression is critical to minimize neurocognitive morbidity. The balance of neurotoxic and neuroprotective factors secreted by brain microvascular endothelial cells, pericytes, astrocytes, neurons and associated neural support cells determine the severity of disorder. HIV-1 viral proteins also directly affect metabolism, function and survival of these cells, but host determinants such as polymorphism and genetic allele variations have also been identified as relevant to individual differences in risk of neurocognitive impairment [1, 16] . As shown in Fig. 4 , mononuclear cells in brain microcapillaries and veins are also exposed to viral proteins and to host-derived neurotoxic and neuroprotective factors. The mononuclear cells in the microvasculature are continuous with the peripheral blood compartment, thus evaluating the transcriptome changes in the PBMCs will provide an indication of neuronal insult. Although systematic analysis can reflect the factors influencing these changes, the analysis is limited by the fact that canonical pathways can be shared between multiple factors and a single factor can induce multiple transcriptome changes. We evaluated global transcriptome changes in cell populations of PBMC, as such an approach will enrich for transcriptome changes that occur across diverse cell types, particularly changes, which are overlapping with diverse cells of the CNS. Zhou et al. [35] reported that the transcriptional changes in PBMCs obtained from HIV-1 patients free of neurological disease were enriched in neurodegenerative pathways suggesting that PBMC-associated gene changes can be reflective of early HIV-1-induced changes. Our results also found transcriptional changes in PBMCs from patients who are HIV-1-seropositive, and HANDnegative that overlap with genes associated with neurological pathology; however, the differentially regulated genes in PBMCs from individuals clinically identified as MND and HAD-positive are enriched for genes related to neuropathogenesis, and these genes are dysregulated to a greater extent (Fig. S2 , HIV-1 invasion and replication in the CNS compartment is associated with release of neurotoxic cytokines and chemokines including IL-1b, TNF-a, IL-8, IL-6, CCL2, and others. These factors damage the blood-brain barrier, which triggers the chemokine feedback loop and further enhances the recruitment of additional inflammatory cells -mainly monocytes/macrophages and associated neuronal toxicity. Furthermore, HIV-1 proteins Tat, Env (gp120), Nef and Vpr induce neuronal apoptosis via direct and indirect mechanism [2] [3] [4] 9, [11] [12] [13] 42, 43] . Thus, there is an overlap in the mechanism of neurotoxicity induced by both viral proteins and inflammatory factors. Although our study is an association study, results identify many factors such as TNFa, IL-1b, IL-6, TGFb and CCL2 that are well established to have a role in HAND pathogenesis. Further, CSF1 and CSF3, which are involved in differentiation and growth of monocyte/macrophage lineage are also identified. This supports results from simian neuroHIV studies, which report that Simian Immunodeficiency Virus (SIV)-infected monocytes originating from bone marrow migrate to the brain and the onset of simian encephalitis correlated directly with the viral load in bone marrow [44] .
EIF2AK3 activation by HIV-1 envelope is reported to induce proinflammatory cytokines in microglial cells and has been identified as a contributor for apoptosis of neurons in in-vitro experiments and is also identified in our analyses. Interestingly, prolactin has an inverse relation with HAND progression. All the factors included in Fig. 4 are pharmacologically amenable targets and are good leads in development of novel therapeutics. MicroRNAs -miR-124-3p, let-7a-5p and miR-210 -were identified in upstream analysis and were differentially regulated. The relative increase in the expression of these miRNAs in HIV-1-seropositive individuals who do not have HAND symptoms, suggests a neuroprotective role for these miRNAs. Previous results from in-vitro experiments as well as SIV model suggests that miR-124-3p has an antiinflammatory role and was found in higher levels in brain of monkeys with HIV encephalitis (HIVE). In addition, in rheumatoid arthritis and primary pulmonary fibrosis models in mouse, miR-124a, was shown to prevent monocyte migration and reduced inflammation, suggesting that miR-124-3p along with other closely related miRNAs in PBMCs inhibit the migration of monocytes across blood-brain barrier in response to CCL2 [45, 46] .
TimePath evaluation of the role of HIV-1 viral proteins identified a greater role for viral proteins in the transcriptome changes associated with HAD development and is further supported by the observation indicating decreased incidence of HAD in patients under combination antiretroviral treatment. In addition, TimePath analysis identified specific HIV-1 viral proteins associated with pathways involved in regulation of proteins identified to be associated with other neurological disease. In summary, based on the correlation of our results with previously identified factors that have a role in in-vitro and animal experiments, we believe a role for these factors in HAND onset and progression. Our analysis cannot rule out other source of these factors that are identified to induce transcriptome changes in PBMCs, though the role of these factors originating from other compartments like gastrointestinal tract, respiratory tract, bone marrow or other areas can potentially increase the risk for onset, progression and severity of HAND. Though our analyses identified the changes in PBMC, it should be noted that monocyte/ macrophage-associated factors and other factors that can cross the blood-brain barrier or regulate its integrity, may have a greater role in HAND pathogenesis. One of the limitations of our study is the missing group of ANI individuals resulting from technical challenges involved in clinically identifying individuals with ANI. Systematic follow-up studies prior to HAND onset may help deduce algorithms that can predict neurocognitive disease outcomes based on transcriptome changes in PBMCs. Follow-up studies in animal models of HIVE and in invitro experiments of novel factors associated with different stages of HAND will help to confirm the role of these factors and will aid in development of novel therapeutics that can prevent and/or delay the onset, progression and severity of HAND.
